Fig. 1
From: Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Prevalence of somatic mutations across respective cancer types. Each dot represents an individual sample and red horizontal lines represent the median number of mutations across samples. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia. Adapted from 27